CN101879274B - 包含红参皂苷提取物和麦冬皂苷提取物的药物组合物、其制备方法和用途 - Google Patents
包含红参皂苷提取物和麦冬皂苷提取物的药物组合物、其制备方法和用途 Download PDFInfo
- Publication number
- CN101879274B CN101879274B CN201010225595A CN201010225595A CN101879274B CN 101879274 B CN101879274 B CN 101879274B CN 201010225595 A CN201010225595 A CN 201010225595A CN 201010225595 A CN201010225595 A CN 201010225595A CN 101879274 B CN101879274 B CN 101879274B
- Authority
- CN
- China
- Prior art keywords
- radix ophiopogonis
- extract
- saponin extract
- red ginseng
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 114
- 150000007949 saponins Chemical class 0.000 title claims abstract description 114
- 239000000284 extract Substances 0.000 title claims abstract description 111
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 84
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title abstract description 3
- 238000000605 extraction Methods 0.000 title description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 4
- 235000017709 saponins Nutrition 0.000 claims description 106
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 60
- 230000008021 deposition Effects 0.000 claims description 43
- 241000208340 Araliaceae Species 0.000 claims description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 230000008030 elimination Effects 0.000 claims description 42
- 238000003379 elimination reaction Methods 0.000 claims description 42
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 41
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 41
- 235000008434 ginseng Nutrition 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 239000012528 membrane Substances 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 27
- 230000001105 regulatory effect Effects 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000008215 water for injection Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 14
- 239000000890 drug combination Substances 0.000 claims description 13
- 229940023488 pill Drugs 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003978 infusion fluid Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 229940068682 chewable tablet Drugs 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- KSIVGTKSVYIZEB-GDUJLLAZSA-N Ophiopogonin A Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](OC(C)=O)[C@H]1O KSIVGTKSVYIZEB-GDUJLLAZSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 2
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 2
- KSIVGTKSVYIZEB-UHFFFAOYSA-N lirioplioside B Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C45C)C)C1CC2C3CC=C4CC(O)CC5OC1OC(C)C(O)C(O)C1OC1OC(C)C(O)C(OC(C)=O)C1O KSIVGTKSVYIZEB-UHFFFAOYSA-N 0.000 claims description 2
- 238000005265 energy consumption Methods 0.000 abstract description 2
- 239000000706 filtrate Substances 0.000 description 28
- 238000001914 filtration Methods 0.000 description 12
- 238000004321 preservation Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000000108 ultra-filtration Methods 0.000 description 12
- 239000003610 charcoal Substances 0.000 description 9
- 150000001298 alcohols Chemical class 0.000 description 8
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 206010020880 Hypertrophy Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000012535 impurity Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229930190017 ophiopogonin Natural products 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010225595A CN101879274B (zh) | 2010-07-12 | 2010-07-12 | 包含红参皂苷提取物和麦冬皂苷提取物的药物组合物、其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010225595A CN101879274B (zh) | 2010-07-12 | 2010-07-12 | 包含红参皂苷提取物和麦冬皂苷提取物的药物组合物、其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101879274A CN101879274A (zh) | 2010-11-10 |
CN101879274B true CN101879274B (zh) | 2012-10-17 |
Family
ID=43051503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010225595A Expired - Fee Related CN101879274B (zh) | 2010-07-12 | 2010-07-12 | 包含红参皂苷提取物和麦冬皂苷提取物的药物组合物、其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101879274B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302420B (zh) * | 2011-07-29 | 2013-08-21 | 金凤燮 | 红参皂苷Rg2组和Rh1组、制备方法及在制备抗皮肤老化化妆品中的应用 |
CN102772382B (zh) * | 2012-08-17 | 2013-10-23 | 山东阿如拉药物研究开发有限公司 | 一种麦冬皂苷d滴丸及其制备方法 |
CN102988399A (zh) * | 2012-12-21 | 2013-03-27 | 周志欢 | 一种药物组合物及用途和制剂 |
KR101505881B1 (ko) * | 2014-11-25 | 2015-03-25 | 김선석 | 홍삼 사포닌 추출물 및 이의 제조방법 |
CN106645535A (zh) * | 2016-12-26 | 2017-05-10 | 河北省药品检验研究院 | 一种红参中5种皂苷类成分的含量测定方法 |
CN110559327B (zh) * | 2019-09-30 | 2021-10-22 | 浙江华缔药业集团有限责任公司 | 一种护肝产品及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101375990A (zh) * | 2007-08-29 | 2009-03-04 | 济南天瑞本草医药科技有限公司 | 一种用于治疗心血管疾病的组合物及其制备方法 |
-
2010
- 2010-07-12 CN CN201010225595A patent/CN101879274B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101375990A (zh) * | 2007-08-29 | 2009-03-04 | 济南天瑞本草医药科技有限公司 | 一种用于治疗心血管疾病的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101879274A (zh) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11007240B2 (en) | Composition containing saponins of Panax ginseng as active ingredient | |
CN101879274B (zh) | 包含红参皂苷提取物和麦冬皂苷提取物的药物组合物、其制备方法和用途 | |
SA04250309B1 (ar) | تركيب صيدلاني لمعالجة الأمراض القلبية وأمراض الأوعية الدموية الدماغية | |
CN105012388A (zh) | 一种防治心脑血管疾病的中药组合物及其制备方法 | |
CN102028700A (zh) | 一种药物组合物及其制备方法 | |
CN1327876C (zh) | 治疗糖尿病及其并发症的中药组合物 | |
CN104434819B (zh) | 注射用乙酰谷酰胺粉针剂药物组合物和制法 | |
CN105125601B (zh) | 一种赶黄草的提取物及其制备方法和用途 | |
CN109091530B (zh) | 紫苏叶提取物在预防或治疗再生障碍性贫血中的应用 | |
CN102293802A (zh) | 一种治疗心血管疾病的药物组合物及其制备方法 | |
CN101428050B (zh) | 一种用于治疗心脑血管系统疾病的活性组合物 | |
CN103405501B (zh) | 三味活血化瘀胶囊的制取方法 | |
CN101947247A (zh) | 一种银杏达莫注射液的制备方法 | |
CN108434166A (zh) | 一种血塞通药物组合物及其制备方法、制剂与应用 | |
CN107261104A (zh) | 促进自体干细胞再生的营养组合物及其制备方法 | |
CN102357180A (zh) | 一种治疗癌症的中药组合物及其制备方法和用途 | |
CN101711793B (zh) | 一种具有治疗心脑血管疾病的药物组合物及其制备方法 | |
CN104324089A (zh) | 各种成分比例稳定均一的大黄总蒽醌及其组合物用于乙型病毒性肝炎的退黄治疗 | |
JP4718443B2 (ja) | Radixnotoginshenのサポニンファミリー静脈内注射液およびその調製方法 | |
CN101152233A (zh) | 一种瓜蒌和银杏叶的药物组合物 | |
CN113995074A (zh) | 一种具有降糖功能的分子精华固体饮料及其制备方法 | |
CN102988461A (zh) | 一种红景天注射液及其制备方法 | |
CN103536698B (zh) | 一种中药组合物在制备治疗血管性痴呆的药物中的应用 | |
CN105380985B (zh) | 一种用于治疗缺血性脑卒中的药物组合物 | |
CN111514212A (zh) | 祖师麻抗肝癌活性总黄酮的制备及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HARBIN JIER BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: XU JUN Effective date: 20120419 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266109 QINGDAO, SHANDONG PROVINCE TO: 150090 HARBIN, HEILONGJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120419 Address after: 533 room 26, building 150090, Pioneer Center, Harbin, Heilongjiang province (Yingbin Road, production place) Applicant after: Harbin Jier Biotechnology Co., Ltd. Address before: 266109, No. 113, sunny road, Chengyang District, Shandong, Qingdao Applicant before: Xu Jun |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HARBIN GLORIA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HARBIN JIER BIOTECHNOLOGY CO., LTD. Effective date: 20150902 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150902 Address after: 150025, 29 Beijing Road, Limin economic and Technological Development Zone, Heilongjiang, Harbin Patentee after: Harbin Gloria Pharmaceuticals Co., Ltd. Address before: 533 room 26, building 150090, Pioneer Center, Harbin, Heilongjiang province (Yingbin Road, production place) Patentee before: Harbin Jier Biotechnology Co., Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Wu Wenting Document name: Notice of termination of patent right |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121017 Termination date: 20200712 |